Novo led the anaemia therapy developer's series A round, which also featured Access Industries subsidiary Access Biotechnology.

US-based haematology startup Disc Medicine closed a $50m series A round on Tuesday that was led by pharmaceutical firm Novo. The round also featured Access Biotechnology, the biotech arm of diversified conglomerate Access Industries, as well as venture capital firm Atlas Venture, Disc Medicine‚Äôs founding investor, which had supplied an undisclosed amount of seed capital…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.